Clinical Trial Update: Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the VISITAG SURPOINT Module with External Processing Unit for paroxysmal atrial fibrillation; study completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Atrial Fibrillation

Drugs mentioned

• VISITAG SURPOINT Module with External Processing Unit

Snippet

Sponsor: Biosense Webster, Inc. | Conditions: Paroxysmal Atrial Fibrillation | Phase 4 | Status: COMPLETED | Results posted: 2022-09-07